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Neoplastic transformation requires changes in cellular identity. Emerging evidence increasingly points to
cellular reprogramming, a process during which fully differentiated and functional cells lose aspects of their
identity while gaining progenitor characteristics, as a critical early step during cancer initiation. This cell iden-
tity crisis persists even at the malignant stage in certain cancers, suggesting that reactivation of progenitor
functions supports tumorigenicity. Here, we review recent findings that establish the essential role of cellular
reprogramming during neoplastic transformation and themajor players involved in it with a special emphasis
on pancreatic cancer.Introduction
During embryonic development, the process of cellular differ-
entiation confers commitment of a cell toward a specific,
terminally differentiated fate. Pluripotent stem cells give rise
to multipotent progenitor cells, which are poised to assume
properties of lineage-restricted precursors in response to
intercellular and intracellular cues. Lineage-restricted precur-
sors undergo final differentiation toward a terminally matured
cell type. Traditionally, it has been accepted that once a cell
has concluded its differentiation path toward a specific fate,
this state is permanent and irreversible. This view of cellular
maturity as an immovable state was challenged by elegant ex-
periments first in frogs and later on mammals that demon-
strated cellular plasticity of mature cells (Gurdon and Melton,
2008). The more recent discovery that adult fully differentiated
cells can be genetically reprogrammed to induced pluripotent
stem cells (iPS), an embryonic stem cell-like state capable of
giving rise to all lineages, further refuted the dogma that the
terminal differentiation state of a cell is irreversibly locked
(Takahashi and Yamanaka, 2006).
Over the last few years, we have learned that cellular dediffer-
entiation might be a common theme in degenerative diseases,
including diabetes (Puri et al., 2014, 2013; Talchai et al.,
2012). Similarly, such erosion of the final differentiation state
of cells has also been observed during malignant progression.
Matured cells with increased plasticity have the ability to ac-
quire some of the genotypic and phenotypic characteristics of
a progenitor-like state or adopt a distinct differentiated state.
In the case of cancer initiation, mutation in key regulatory genes
is one of the major drivers of increased plasticity. Following an
oncogenic insult, a mature cell may undergo loss of cellular
identity on its way to neoplasia andmaintain this abnormal plas-
ticity through the malignant stages. Loss of cellular identity
comes in two flavors: dedifferentiation, defined as loss of
mature functionality, and transdifferentiation, characterized by
a change in cellular identity toward a different mature cell
type. Of note, dedifferentiation can precede transdifferentiation
toward a distinct cellular fate (Puri et al., 2014). In this review, we
will discuss how loss of the defined differentiation state is
emerging as a common step toward cellular transformation in
many different cancers.674 Developmental Cell 35, December 21, 2015 ª2015 Elsevier Inc.Defective Differentiation States in Cancer
Emergence of a progenitor-like state promotes cellular trans-
formation and tumor formation. This raises the question as to
whether such a progenitor state can be modulated for thera-
peutic purposes. In other words, is it possible to revert tumor
cells toward a quiescent, matured state with reduced or absent
malignant potential? In a seminal study, G. Barry Pierce pro-
vided evidence that malignant cells indeed can be differenti-
ated into benign, post-mitotic cells (Pierce and Wallace,
1971). This finding not only conceptualized the origin of differ-
entiation therapy but also established the rationale of studying
initial reprogramming of cells at the inception of cancer. The
underlying theory of clinically targeting defective differentiation
states by promoting maturation was successfully validated in
acute promyelocytic leukemia (APML), a lethal form of hemato-
logical malignancy driven by an incomplete differentiation pro-
gram. APML is characterized by reciprocal translocation of
chromosome arms 15 and 17, which results in the fusion of
the promyelocytic leukemia gene (PML) with the retinoic acid
receptor gene (RAR-a) (Borrow et al., 1990; Larson et al.,
1984). The resulting PML-RARa homodimers repress target
genes essential for granulocytic differentiation, thus holding tu-
mor cells back in a progenitor-like state. Anthracycline-based
chemotherapy, which inhibits the proliferation of malignant
cells, used to be the only way to treat APML, but the benefit
to patients was limited and often short lived. One of the charac-
teristics of APML is the abnormal accumulation of promyelo-
cytes within the bone marrow of patients (Wang and Chen,
2008). This observation led to the hypothesis that a block in
granulocytic differentiation caused by the fusion protein might
act as a driving force for APML formation. A major break-
through in APML research was the finding that leukemia cells
can be induced to undergo full differentiation upon treatment
with certain agents such as all-trans retinoic acid (ATRA) (Breit-
man et al., 1981, 1980). As a consequence, patients receiving
ATRA exhibit a gradual transition of leukemic promyelocytes
toward terminal granulocytes resulting in long-lasting and
sometimes curative responses (Tallman et al., 1997; Warrell
et al., 1991). This is perhaps one of the best-documented ex-
amples in which tumor cells are successfully targeted based
on their defective differentiation state.
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Successful application of differentiation therapy has also been
reported in solid malignancies such as myxoid liposarcoma
(MLS), a common tumor of adipose tissue that results from an
impediment in the adipogenic differentiation program. MLS is
characterized by the reciprocal translocation between the FUS
and CHOP genes, resulting in a fusion protein, FUS-CHOP (Cro-
zat et al., 1993; Pe´rez-Losada et al., 2000; Rabbitts et al., 1993).
CHOP belongs to the C/EBP transcription factor family and is
involved in adipogenesis (Batchvarova et al., 1995; Ron and
Habener, 1992), whereas FUS is a protein component of the nu-
clear riboprotein complex with an RNA binding motif (Crozat
et al., 1993; Rabbitts et al., 1993). The hybrid protein functions
as an abnormal transcription factor capable of deregulating
CHOP target genes, including inactivation of those required for
the lipogenic terminal differentiation programs (Adelmant et al.,
1998). Trabectedin, a compound isolated from the sea squirt
Ecteinascidia turbinata, promotes the transition from immature
non-lipogenic spindle cells to mature lipoblasts by removing
the fusion protein from promoters of genes critical for adipogen-
esis. As a consequence, the transcriptional block toward
matured state is abolished, leading to a reduction in tumor
burden (Forni et al., 2009). Thus, similar to hematological malig-
nancies, solid tumors displaying attributes of progenitor-like
states also respond to differentiation therapy.
Loss of Cellular Identity in Gastrointestinal Tumors
Chromosomal rearrangements resulting in fusion of specific
genes and subsequent generation of aberrant fusion proteins
evoke a defective differentiation program in both MLS and
APML. However, both these malignancies display minimal addi-
tional genetic abnormalities. This brings up the pertinent ques-
tion as to whether defective differentiation is commonplace in
other tumor types, including those characterized by multiple
‘‘driver’’ mutations. If so, does loss of cellular identity only
happen in cells at intermediate stages of development (like
APML or MLS) or also in terminally matured cells? Genetically
engineered mouse models (GEMMs) that mimic the human
diseases have provided ample evidence that loss of mature
cellular identity is an obligatory step for many types of solid tu-
mor malignancies.
For example, hepatocellular carcinoma (HCC) often presents
with features of a multipotent progenitor-like state arising from
matured hepatocytes. Deregulation of the Hippo signaling
pathway has recently been shown to transform hepatocytes
into atypical duct cells and promote progression to HCC. Line-
age tracing studies of hepatocytes in mice with hyper-activated
Hippo pathway signaling (either through ectopic expression of
the Hippo effector Yap1, or inactivation of Nf2, a factor upstream
of the Hippo pathway) revealed reprogramming of hepatocytes
into ductal cells bearing characteristics of progenitors (Camargo
et al., 2007; Yimlamai et al., 2014). These hepatocyte-derived
progenitors retained their plasticity, as they could reassume
the mature hepatocyte state once normal Hippo signaling
was reestablished. A recent proof-of-concept study further
demonstrated that Yap1 deletion in HCC completely blocks
cell proliferation and atypical ductal cell expansion followed by
gradual reactivation of a hepatocyte differentiation program (Fi-
tamant et al., 2015). Under these conditions, HCCs change theirDmorphology by forming nodules resembling groups of regenera-
tive hepatocytes. Thus, the presence of dedifferentiated cells in
HCCs and the loss of the malignant phenotype upon redifferen-
tiation toward hepatocytes point to the progenitor state as crit-
ical for tumor development and maintenance.
Pancreatic Ductal Adenocarcinoma
Genetic reprogramming and loss of cellular identity are also crit-
ical early steps during the initiation of another gastrointestinal
cancer type, pancreatic ductal adenocarcinoma (PDA). PDA is
one of the deadliest malignancies, in large part due to the
absence of specific early symptoms that would facilitate the
timely diagnosis at the initial stage of the disease (Hezel et al.,
2006). Thus, efforts to define the molecular mechanisms that un-
derlie the initiation of PDA are highly relevant for early detection
and timely treatment.
The pancreas is a heterogeneous organ consisting of exocrine
and endocrine compartments (Puri and Hebrok, 2010). Pancre-
atic exocrine tissue comprises acinar cells that synthesize diges-
tive enzymes, ductal cells that transport the acinar-derived en-
zymes to the duodenum, and terminal duct cells/centroacinar
cells present at the interface of the acinar and ductal systems.
The endocrine part consists of cellular aggregates, known as is-
lets of Langerhans, which are composed of hormone-secreting
cells. While tumors can form from the endocrine region of the
pancreas, the most common cancer is the exocrine-derived
PDA. PDA can arise from distinctive non-invasive lesions classi-
fied as pancreatic intraepithelial neoplasia (PanIN), mucinous
cystic neoplasm (MCN), and intraductal papillary mucinous
neoplasm (IPMN) (Hezel et al., 2006). Understanding the process
bywhich normal pancreatic cells transition toward neoplasia and
subsequently PDA offers the opportunity to identify early bio-
markers or novel therapeutic targets that could be exploited to
change the course of the disease. As discussed below, we will
define different types of PDA neoplasia while summarizing
what is known about the cellular transition that occurs during
the development of each kind.
PanIN-Derived PDA
PanINs are a frequently diagnosed lesion type that result in
aggressive PDA with a 5-year survival rate of a dismal 5% (Hezel
et al., 2006). Sophisticated GEMMs have been developed that
accurately mimic PanIN to PDA formation, thus allowing us to
more precisely track the origin and progression of PanIN lesions.
Mutations in KRAS serve as the oncogenic driver in 95% of PDA
patients (Almoguera et al., 1988; Smit et al., 1988). In a landmark
study that revolutionized the way mouse models of pancreatic
cancer were generated, Hingorani and colleagues placed the hu-
man KRAS gene carrying an oncogenic G12D mutation that
keeps the enzyme in a constitutively active state into the endog-
enousKras locus inmice. Expression of the oncogenic version of
Kras was initiated upon Cre-mediated elimination of a preceding
stop cassette. Targeted expression of oncogenic Kras in pancre-
atic progenitor cells (around embryonic day 8.5–9) induces
lesions in the mature organ recapitulating the full spectrum of
human PanIN (Hingorani et al., 2003). Identifying the cellular
origin for these lesions could provide critical information
regarding the early detection of PDA and could suggest new
therapeutic opportunities.evelopmental Cell 35, December 21, 2015 ª2015 Elsevier Inc. 675
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Considering that mutant Kras is expressed in the entire pancre-
atic epithelium in the above-mentioned GEMM model, this ge-
netic approach could not delineate as to whether a specific
cell type was particularly sensitive to oncogenic Kras-mediated
transformation. Therefore, to explore the cellular precursors of
PanINs, several GEMMs with promoters of diverse pancreatic
genes marking specific mature cell types have been generated
over time to ectopically express oncogenic Kras in distinct
pancreatic cell types (see Table S1 for all the relevant GEMM
models and their corresponding references). Interestingly,
different cell types have been attributed as the cell of origin for
PanIN, and the data supporting each cell type are discussed
below.
Evidence for a Ductal Origin of PanIN
Histological analysis of PDA identified associated PanINs as le-
sions that appeared to be in continuous contact with the existing
ductal tree of the pancreas, suggesting that PanIN-derived PDA
originates from duct cells. Surprisingly, constitutively expressing
a different oncogenic version of Kras (KrasG12V) under control of
the duct-specific Cytokeratin 19 promoter exhibited only occa-
sional pancreatic ductal hyperplasia (Brembeck et al., 2003).
Pancreatic duct cells (PDCs) purified from these animals also
did not display any difference in growth or cell-cycle distribution
compared to wild-type PDCs (Schreiber et al., 2004). When
oncogenic Kras (KrasG12D) was expressed via Cre-mediated
recombination in adult PDCs in an inducible manner (CK19Cre
ERT), a small number of mucinous metaplasia with characteris-
tics of early PanIN lesions was observed. Conclusive evidence
demonstrating that these PanINs were true lesions was not ob-
tained, as progression toward the PDA state was not observed
(Ray et al., 2011). In vitro expression of mutant KrasG12V in
quiescent PDCs was found to stimulate S-phase entry, increase
cell size, and cause epithelial to mesenchymal transition (Agbu-
nag and Bar-Sagi, 2004). When these primary ductal cells ex-
pressing oncogenic Kras were transplanted orthotopically into
the mouse pancreas, they formed ductal structures resembling
early PanIN lesions but lacked full tumorigenic potential (Lee
and Bar-Sagi, 2010; Pylayeva-Gupta et al., 2012). Thus, while
activation of oncogenic Kras in PDCs was sufficient to induce
mitogenic and morphogenic responses, full transformation to
PDA was not observed.
More recently, organoid cultures were established from small
intra-lobular ducts of normal and KrasG12D-expressing mice.
Spheres containing cells expressing oncogenic Kras formed
PanIN-like structures with columnar morphology upon ortho-
topic injection into rodent pancreas (Boj et al., 2015). Similar
results were obtained with human tissue. Notably, human orga-
noids gave rise to low and high-grade PanIN lesions within a
month and progressed to full-blown PDA within several months
after orthotopic transplantation into immune-compromised
mice, demonstrating that human duct cells are competent to
form PanIN lesions when proper oncogenic cues are present.
The apparent discrepancy between this study by Boj et al. and
the aforementioned mouse models that did not report efficient
PanIN-PDA formation has not been addressed fully. It is possible
that in vitro culture conditions are more conducive for Kras-
mediated oncogenic transformation due to the lack of other sup-676 Developmental Cell 35, December 21, 2015 ª2015 Elsevier Inc.porting tissues present in vivo, and future experiments will have
to resolve these issues. Furthermore, a recent report by Bailey,
Leach, and colleagues presents interesting findings that do
demonstrate the potential for adult PDCs to serve as progenitors
for PDA in GEMMs (Bailey et al., 2015). While expression
of oncogenic Kras alone in mature duct cells did not elicit
neoplasia, concomitant expression of KrasG12D with two alleles
of a gain-of-function mutation in p53 (p53R127H) was sufficient
in initiating PDA formation frommature duct cells. Of note, simul-
taneous expression of just one p53R127H allele with oncogenic
Kras did not result in PDA, suggesting a requirement for a certain
level of p53 activity in duct cells to promote PDA development. In
addition, and somewhat peculiarly, pancreatic duct-derived
neoplasia did not progress via PanIN lesions. Thus, as most
autochthonous mouse models did not show the full spectrum
of PanIN-PDA, the alternative hypothesis that non-duct cells
might be the predominant source of PanIN-derived PDA has
gained momentum.
Acinar Cells as Cells of Origin for PanIN
Acinar cells make up the vast majority of pancreatic epithelial
cells. In support of acinar cells as the origin for PanINs, and in
line with the proximity of PanIN cells with ductal cells, it has
been shown that acinar cells are vulnerable toward transdifferen-
tiation to a ductal state. Upon varying insults, acinar cells readily
lose functionality and enter into an intermediate dedifferentiation
state in which they abandon their identity but have not yet
adopted ductal features. Subsequently, a transdifferentiation
event leads to adoption of true duct-like characteristics by the
enzyme-producing cells. Such a conversion is described as
acinar to ductal metaplasia (ADM). Support for this notion comes
from early in vitro and in vivo evidence suggesting that injury or
oncogenic transformation can drive acinar cells toward a ductal
phenotype (Arias and Bendayan, 1993; De Lisle and Logsdon,
1990; Grippo and Sandgren, 2000; Hall and Lemoine, 1992;
Vila et al., 1994; Yuan et al., 1997). Acinar transdifferentiation
into ductal metaplasia can lead to premalignant lesions as
shown by EGFR, TGF-a, SV40 large T antigen, or KrasG12D
expression in pancreatic acinar cells (Bockman and Merlino,
1992; Grippo et al., 2003; Ornitz et al., 1987; Sandgren et al.,
1990; Tuveson et al., 2006; Wagner et al., 2001, 1998). Using
Nestin-Cre animals, Murray Korc’s group provided further sup-
port for the notion that acinar cells, or their progenitors, can
give rise to neoplastic cells with ductal features (Carrie`re et al.,
2007). Furthermore, subsequent studies using Elastase CreERT
or proCPA1; CreERT transgenic mice that express Cre recombi-
nase specifically in adult acinar cells following Tamoxifen admin-
istration confirmed that Kras activation in mature acinar cells
induces PanIN lesions in a manner similar to ubiquitous Kras
activation within the pancreatic epithelium (De La O et al.,
2008; Gidekel Friedlander et al., 2009).
While these data collectively provided strong support that
acinar cell can serve as a progenitor for PanINs, conflicting re-
sults were obtained with a different version of oncogenic Kras
(KrasG12V). Ectopic expression of KrasG12V in developing
acinar cells also led to spontaneous generation of PanIN and
PDA, but adult pancreatic acinar cells were refractory to Kras-
mediated transformation. In humans, pancreatitis and inflamma-
tion have been recognized as strong risk factors for PanIN and
Figure 1. Transition betweenCellular States
during PanIN- and IPMN-Derived PDA
Acinar, ductal, or centroacinar cells can give rise to
PanINs. However, based on the current observa-
tions, acinar cells have been emerged as the
predominant source for PanIN-derived PDA. On
the other hand, current evidence clearly indicates
duct cells as the cell of origin for IPMN. Both
neoplasia are characterized by the erosion of
the mature differentiation state of their respective
cells of origin. While acinar cells undergo trans-
differentiation toward a duct-like state before
PanIN formation, duct cells dedifferentiate to a
lesser degree and retain aspects of the duct line-
age during IPMN. Notably, both dedifferentiation
programs display some features of the ductal
lineage, suggesting that exocrine neoplasia might
have to progress through a common ‘‘bottle neck,
duct-like’’ state.
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lenged with caerulein, a cholecystokinin analog capable of in-
ducing pancreatitis associated with fibrosis and inflammation,
subsequent expression of KrasG12V did induce PanIN and
PDA in postnatal acinar pancreas (Guerra et al., 2007). In
contrast, by using two different transgenic lines permitting
ectopic expression of KrasG12D in adult acinar cells (Elastase
CreERT or Mist1 CreERT), Maitra and colleagues observed
spontaneous development of PanIN lesions in the absence of
concurrent exocrine injury (Habbe et al., 2008). The reason for
the discrepancies in the observed phenotypes remains elusive,
but distinct transforming capacities between G12V and G12D
may partially explain the differences. Nonetheless, the general
consensus of these studies supports the notion that acinar cells
respond to oncogenic Kras, either alone or in combination with
inflammatory insults, by transdifferentiating toward a ductal
phenotype prior to PanIN formation (Figure 1).
A recent study directly compared the propensity of ductal and
centroacinar versus acinar cells to undergo dedifferentiation and
subsequent transformation by oncogenic Kras (Kopp et al.,
2012). Forced expression in either adult acinar cells (Ptf1a Cre-
ERT2) or adult duct and centroacinar cells (Sox9 Cre-ERT2)
induced PanIN lesions that arose predominantly from acinar
but not ductal or centroacinar cells. Even when challenged
with pre-neoplastic insults, such as caerulein-induced acute
pancreatitis, KrasG12D-expressing duct cells showed only a
low propensity to form PanIN lesions.
Centroacinar Cells as Progenitors for PanIN
In addition to the above-described acinar-centric theory of
PanIN formation, others have suggested centroacinar cells
as progenitors for PanIN and PDA development. Centroacinar
cells display several characteristics that set them apart from
other mature pancreatic cell types, including their location
that is confined to the transition zone between duct and acinar
cells and their propensity to express molecular markers of em-Developmental Cell 35, Dbryonic progenitor cells, including Notch
signaling (Kopinke et al., 2011; Afelik
et al., 2012; Kopinke et al., 2012). Further-
more, their ability to form replicating
spheres capable of differentiating into allpancreatic cell types when cultured in vitro has supported the
notion that these cells might possess adult stem cell properties,
a notion that has not been confirmed in vivo (Rovira et al., 2010).
However, centroacinar cells have been implicated in neoplastic
transformation (Stanger et al., 2005). Elimination of Pten expres-
sion, a tumor suppressor gene, instead of ectopic expression of
mutant Kras as the oncogenic driver, led centroacinar cells to
transdifferentiate into ductal cells and formed mucinous meta-
plasia as well as PanIN lesions. An intriguing theory that arises
from these findings is that the difference in the tumor-initiating
event determines whether duct, centroacinar, or acinar cells
serve as the origins for PanIN and PDA development.
Predisposition of Epithelial Subtypes and Cancer
Stem Cell
Although the majority of studies point toward fully differentiated
exocrine cells as precursors of PanIN-PDA, some reports sug-
gest that a subset of cells exists that might be more susceptible
to oncogenic transformation. While the presence of true mature
pancreatic stem cells, defined as cells capable of expansion,
maintenance of a progenitor phenotype, and differentiation into
multiple mature cell types have not been clearly demonstrated,
there is emerging evidence that distinct subsets of cells residing
within the pancreatic epithelium might have higher predisposi-
tion for dedifferentiation. For example, doublecortin and Ca2/
calmodulin-dependent kinase-like 1 (Dclk1) is expressed in a
small percentage of duct cells, and these cells are associated
with progenitor-like function (May et al., 2010). Additional studies
have shown that Dclk1 high cells have enhanced PanIN sphere-
forming ability, suggesting a propensity for such cells to undergo
neoplastic transformation (Bailey et al., 2014). It remains to be
explored as to whether Dclk1 high cells have already initiated
an early dedifferentiation program that predisposes them for
PanIN formation. The finding that Dclk1 is among a select group
of factors, including CD24, CD44, and ESA, expressed both in
early PanIN lesions and ‘‘cancer stem cells’’ present in fullyecember 21, 2015 ª2015 Elsevier Inc. 677
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Figure 2. Factors Regulating Exocrine Cell
Fate Conversion
(A) During pancreas development, several tran-
scription factors regulate the differentiation
cascade that converts progenitors into fully
differentiated state in a concerted, regulated
manner. Many of these same factors were de-
regulated during cancer initiation and progression.
Factors marked in red have been implicated in
cellular dedifferentiation during oncogenic trans-
formation.
(B) Expression analysis of lineage-specifying
transcription factors during acinar or ductal
dedifferentiation.
Developmental Cell
Reviewdeveloped tumors further suggests that a select sub-population
of pancreatic epithelial cells could harbor progenitor functions
that might be maintained over time. Cancer stem cells share
the ability for unrestrained self-renewal like normal stem cells
and can be identified and purified via expression analysis of spe-
cific cell surface markers such as CD24, CD44, CD133, EPCAM,
ESA, c-Met, Aldh1, Lgr5, and Dclk1 (Hermann et al., 2007; Li
et al., 2007; Kim et al., 2011, Sureban et al., 2011; Mizuno
et al., 2013; Ischenko et al., 2014). Future studies will have to
determine whether cancer stem cells truly represent a distinct
cell population or whether the expression of the cellular markers
and the associated renewal properties can be attained by other
tumor cells under certain conditions.
Humanized Models for PDA
Current evidence indicates that all exocrine pancreas cell types
possess the ability to transform into PanIN and PDA, albeit to
varying degrees. While acinar cells have emerged as the pre-
dominant source for PDA fromGEMM studies, one cannot disre-
gard the possibility that murine pancreatic cell types behave
differently than their human counterparts with regard to their sus-
ceptibility to oncogenic transformation. The advent of human
stem cell technology has opened up opportunities to study the
initiation of pancreatic neoplasia in the human context. Zaret
and colleagues generated human iPS cells from primary pancre-
atic epithelial cells isolated from PDA, thereby developing a ver-
satile model in which late stage tumors can be reprogrammed to
recapitulate early stages of the disease (Kim et al., 2013). In
another study, Muthuswamy and colleagues introduced three-
dimensional culture conditions to induce differentiation of human678 Developmental Cell 35, December 21, 2015 ª2015 Elsevier Inc.pluripotent stem cells into exocrine orga-
noids that can be used to model human
PDA (Huang et al., 2015a). These efforts
usher in an era in which human models
of PDA can be exploited in connection
with existing GEMMs to study early and
late stages of disease initiation and pro-
gression (Kim and Zaret, 2015).
The Role of Lineage-Specifying
Transcription Factors in Regulating
Cellular Identity
Increasing evidence suggests that acinar
dedifferentiation proceeds via an orches-
trated process that involves loss of
cellular identity followed by the acquisition of ductal properties.
In molecular terms, the dedifferentiation program is associated
with loss of acinar markers such as Nr5a2, Mist1, and Ptf1a and
increased expression of ductal markers such as Sox9 and Hnf6
(Figure 2). Functional studies have shown that these transcrip-
tion factors are not just markers of dedifferentiation but that
they profoundly regulate acinar cell identity and prevent Kras-
mediated oncogenesis. For example, Nr5a2, a member of the
nuclear receptor family of intracellular transcription factors, is
required for securing the fate of the enzyme-producing cells,
as its deletion in the pancreas epithelium leads to destabiliza-
tion of the mature acinar differentiation state and loss of regen-
erative capacity following acute pancreatitis (Flandez et al.,
2014; von Figura et al., 2014b). In the adult pancreas, Nr5a2
co-operates with the pancreas transcription factor 1-L complex
(PTF1-L) to regulate acinar-specific gene expression (Holm-
strom et al., 2011). PTF1-L is a tripartite complex in which
the basic helix-loop-helix protein (bHLH) protein Ptf1a serves
to convey target specific gene expression. Similar to Nr5a2,
deletion of Ptf1a in the pancreas also promotes rapid ADM
(Krah et al., 2015). Another bHLH transcription factor, Mist1,
is expressed in pancreatic acinar cells and has also been
shown to maintain their function, stability, and identity (Pin
et al., 2001; Shi et al., 2013). Thus, a defined set of acinar tran-
scription factors prevents transdifferentiation toward other
pancreatic cell types, most notably duct cells. Interestingly,
sustained expression of these acinar-specific transcription fac-
tors appears critical in impairing oncogenic Kras-driven ADM
and neoplastic transformation. In summary, these observations
support the concept that erosion of the acinar differentiation
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Reviewstate is necessary to provide a permissive environment for
Kras-driven ADM and PanIN development.
In addition to signals that maintain acinar identity, a different
set of transcription factors actively promotes acinar dedifferenti-
ation. Expression of proteins normally absent in enzyme-produc-
ing cells results in their transdifferentiation toward ductal proper-
ties. For example, Pdx1, a transcription factor mostly confined to
b cells in the adult pancreas, leads to cell-autonomous acinar to
ductal transition when artificially expressed in acinar cells from
embryonic stages onward (Miyatsuka et al., 2006). Similarly,
inappropriate expression of Sox9 in acinar cells, a transcription
factor that maintains duct cell identity, destabilizes cellular iden-
tity of acinar cells, promotes expression of ductal genes, and
greatly increases Kras-driven ADM. The observation that dele-
tion of Sox9 in KrasG12D-expressing adult acinar cells largely in-
hibits PanIN formation further suggests a critical function for the
transcription factor in the transition toward a ductal fate (Kopp
et al., 2012). Support for this notion comes from human studies
that have noted upregulation of this key duct marker during
ADM (Kopp et al., 2012). Prrx1, a nuclear homeodomain tran-
scription factor upregulated during acinar dedifferentiation,
binds to the Sox9 promoter and positively regulates Sox9
expression (Reichert et al., 2013). Furthermore, Hnf6, another
duct-specific transcription factor, suppresses acinar markers
while inducing ductal markers such as Sox9 (Pre´vot et al.,
2012). Thus, initiating a transdifferentiation cascade toward the
duct state appears to be accomplished through activation of
just a few transcription factors at the top of a hierarchical
signaling cascade. Complete ductal reprogramming, however,
requires the presence of oncogenic Kras. Therefore, promoting
acinar transdifferentiation toward a ductal state needs to go
hand-in-hand with oncogenic stimuli to induce lasting ADM,
neoplasia, and PDA.
Role of Oncogenic Kras in Cellular Reprogramming
As oncogenic Kras is central to pancreatic cancer initiation,
delineating the function of the various Kras-driven pathways in
the dedifferentiation process has been a major research focus.
Using a mouse model that permitted pancreas-specific, tempo-
rally regulated and reversible expression of mutant Kras, Ma-
gliano and colleagues showed that oncogenic Kras reversibly
altered normal epithelial differentiation following tissue damage
(Collins et al., 2012). Inactivation of Kras in established acinar-
derived PanINs leads to their redifferentiation into acinar cells
and eventually PanIN regression. Oncogenic Kras signaling in
PDA primarily involves three major pathways: the (1) Raf/MEK/
ERK, (2) PI3K/Pdk1/Akt, and (3) Ral guanine nucleotide ex-
change factor pathways (Eser et al., 2014). Active MAPK
signaling is required to maintain the KrasG12D-driven dediffer-
entiated acinar state in PanIN lesions. Conversely, pharmacolog-
ical inhibition of MAPK pathway effector MEK1/2 drives PanIN
cells to re-differentiate into acinar cells (Collins et al., 2014).
Several other MAPK pathway factors that are required for Ras
transformation such as Protein kinase C iota, serine threonine ki-
nase Protein kinase D1, and immediate early response family
IER3 have also been shown to be required for Kras-mediated re-
programming of enzyme-producing cells (Garcia et al., 2014;
Liou et al., 2015; Scotti et al., 2012). Cell-autonomous PI3K
and PDK1 signaling, the second Kras regulated pathway, servesDas a key effector of oncogenic Kras-driven ADM (Eser et al.,
2013; Ying et al., 2011). Likewise, Ral-GDS, a component of
the third arm of Ras effector signaling, has been implicated in
the early dedifferentiation program. Ral1 target Rac1 mediates
F-actin redistribution and actin reorganization, which is required
for morphologic changes of acinar cells undergoing ductal meta-
plasia (Heid et al., 2011). Thus, all three signaling cascades
downstream of oncogenic Kras are involved in aspects of ADM
and PanIN formation.
In addition, several other pathways in the Ras interactome,
such as STAT3 and EGFR signaling, have been shown to play
an integral part in the ADM process (Corcoran et al., 2011; Fu-
kuda et al., 2011; Lesina et al., 2011;Siveke et al., 2007;Ardito
et al., 2012). Summarily, available evidence reinforces the con-
cept of a coordinated erosion process in mature acinar cells
preceding the oncogenic transformation driven by mutant Kras
toward PDA.
Embryonic Signaling Pathways Involved in Acinar
Reprogramming
Oncogenic Kras-mediated cellular dedifferentiation often in-
volves hijacking of signaling pathways that play a crucial role in
pancreatic organogenesis such as Notch, Wnt, Hedgehog (Hh),
and small non-coding RNA (Dessimoz et al., 2005; Hebrok
et al., 2000; Heiser et al., 2006; Jensen, 2004; Murtaugh et al.,
2005; Wells et al., 2007; Lynn et al., 2007). These pathways
play critical functions during oncogene-driven acinar dedifferen-
tiation (Morris et al., 2014; Pre´vot et al., 2013; Wang et al., 2014;
Fendrich et al., 2008). For example, activated Notch signaling
and oncogenic Kras co-operate in promoting rapid reprogram-
ming of acinar cells into a duct-like phenotype (De La O et al.,
2008; Greer et al., 2013). In contrast to the positive role of Notch
during ADM, b-catenin, a critical mediator of the canonical Wnt
signaling cascade, inhibits Kras-dependent reprogramming of
acinar cells (Heiser et al., 2008; Morris et al., 2010). Thus, ADM
is regulated by positive and inhibitory signals from embryonic
pathways that guide exocrine pancreas formation.
Epigenetic modifiers and chromatin regulators too have been
implicated in oncogenic Kras-driven loss of acinar identity. For
example, Brg1, an ATP-dependent catalytic subunit of the
SWI/ SNF chromatin remodeler complex, is required for onco-
genic Kras-driven ductal metaplasia (von Figura et al., 2014a).
Likewise, Sirtuin 1, a NAD-dependent histone deacetylase, reg-
ulates ADM. Sirt1-mediated deacetylation of b-catenin and
acinar-specific transcription factor Ptf1a leads to a reduction
of the expression of both factors and subsequently to a loss of
the mature acinar state, thus placing Sirt1 atop a hierarchical
cascade that controls mature acinar identity (Wauters et al.,
2013).
Finally, several environmental stimuli such as smoking and
chronic alcohol exposure, posited to be risk factors for PDA,
have also been implicated in ADM (Huang et al., 2015b). For
example, smoking, one of the major risk factors for PDA forma-
tion, induces dedifferentiation of acinar cells by activating AKT-
ERK-MYC signaling (Hermann et al., 2014). This cascade inhibits
the activity of Gata6, a transcription factor previously shown to
play an important role in maintaining the adult acinar cell
compartment (Martinelli et al., 2015). Summarily, these data
demonstrate how oncogenic cues collaborate with a complexevelopmental Cell 35, December 21, 2015 ª2015 Elsevier Inc. 679
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matured acinar state. More importantly, identifying these critical
nodes of deregulation provides us with an opportunity to clini-
cally target the defective differentiation states of tumor cells.
IPMN-Derived PDA
Besides the vast majority of PDAs being derived from PanIN
lesions, there are a small number of PDA cases, which emerge
from other neoplastic subtypes such as mucinous cystic
neoplasm (MCN) and intraductal papillary mucinous neoplasm
(IPMN). Mouse models that faithfully recapitulate human MCN
are limited, thus precluding proper identification of their cellular
origin (Izeradjene et al., 2007). One study suggested MCN to
be formed from acinar cells; however, whether that process in-
volves any dedifferentiation step remains to be explored (Sano
et al., 2014).
IPMN formation has been observed in several transgenic
mouse models, including those with concomitant activation of
TGF-alpha, stimulation of Gs-alpha subunit GNAS, deletion of
Brg1, or attenuated Smad4 expression in the context of onco-
genic Kras (Bardeesy et al., 2006; Siveke et al., 2007; Taki
et al., 2015; von Figura et al., 2014a). Of particular interest is the
observation that despite distinct morphological and gene
expression signatures of IPMN and PanIN lesions, the resulting
tumors are both classified as PDA. This raises the question of
whether the early steps of IPMN and PanIN initiation are shared.
To delineate the cellular origin of IPMN, Cre recombinase-driven
expression of oncogenic Kras and elimination of Brg1 was
directed specifically to adult duct or acinar cells. Acinar-driven
animals did not display any IPMN lesions, suggesting limited po-
tential for enzyme-producing cells to undergo such neoplasia. In
contrast, IPMN-like progenitor duct atypia as well as occasional
IPMN formationwere found inmicewith oncogenic Kras/elimina-
tion of Brg1 in duct cells (von Figura et al., 2014a). Considering
that IPMN lesions retain ductal characteristics, the recent finding
that pancreatic duct cells also lose their mature differentiation
state en route to oncogenic transformation was somewhat unex-
pected (Roy et al., 2015). Duct-derived IPMN cells were found to
lose expression of many adult ductal markers such as HNF1b,
Hnf6, and Sox9. Loss of Sox9 expression appears to be particu-
larly important for duct identity, a hypothesis that was confirmed
upon ectopic expression of Sox9 that prevented IPMN formation.
These observations point to the deterioration of cellular iden-
tity as a shared and critical process during PanIN and IPMN for-
mation. While acinar cells undergo transdifferentiation toward a
‘‘duct-like’’ state before PanIN formation is initiated, duct cells
dedifferentiate to a lesser degree and retain aspects of the
duct lineage during IPMN development. Notably, both dediffer-
entiation programs display some features of the ductal lineage,
raising the tantalizing hypothesis that exocrine neoplasia might
have to progress through a common ‘‘bottle neck, duct-like’’
state (Figure 1). Defining in detail the dedifferentiated cells
emerging from either acinar or duct cells should enable us to
tailor therapeutic regimens for PDA arising from divergent
neoplastic lesions.
Therapeutic Implications
A central question emerges from the above studies: is it possible
to reverse the dedifferentiated state of pancreatic cancer cells680 Developmental Cell 35, December 21, 2015 ª2015 Elsevier Inc.and sensitize them to chemotherapy? Successful application
of retinoic acid for APML or trabectedin for MLS indeed holds
promise for ‘‘differentiation-targeted’’ therapy. One can argue
that APML or MLS, unlike gastrointestinal cancers, are single
karyotype diseases caused by a characteristic fusion gene that
drives their tumorigenicity. However, similar arguments could
be made for oncogenic Kras, the predominant oncogene for
PDA. Fortunately, with the development of sophisticated
GEMM, we are now equipped to analyze the different develop-
mental stages during carcinoma progression. The information
gathered from these mouse models will inform us about the crit-
ical nodes of tumor development that can be targeted. For
instance, during pancreatic cancer progression, the progenitor
genes Pdx1 andHnf4a are upregulated. JQ1, a bromodomain in-
hibitor, represses expression of these genes and activates
mature duct markers (Roy et al., 2015). As a consequence,
JQ1 reduced IPMN-PDA tumor burden in animals, possibly
through reactivation of a cellular differentiation program. In
support of the broader use of such an approach, a recent re-
port showed that by overexpressing the bHLH protein E47,
neoplastic cells reverted to an acinar state with reduced PanIN
tumorigenicity (Kim et al., 2015). Perhaps the most important ev-
idence comes from the use of MAPK inhibitors, which directly
antagonize the oncogenic Kras pathway. When the MAPK-ERK
pathway was inhibited pharmacologically in Kras-driven animal
models, neoplastic cells were able to reverse to their mature
acinar differentiation state (Collins et al., 2014). Thus, strength-
ening or reestablishing the cellular identity may be exploited as
a novel therapeutic avenue for PDA treatment.
In their widely cited ‘‘Hallmarks of Cancer’’ review, Weinberg
and Hanahan identified several characteristics shared by
most cancer cells, such as replicative immortality, evasion of
apoptosis, escape from immune cell recognition, and aberrant
cellular energetics (Hanahan and Weinberg, 2011). Current ther-
apeutic interventions attempt to target the principal nodes of the
signaling pathways that lead to the disruption of these specified
hallmarks of cancer. However, in light of new and emerging evi-
dence, a ‘‘defective dedifferentiation state’’ may be a hallmark of
many cancers that can be targeted therapeutically with the goal
of reverting tumor cells toward a normal or more benign state.
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